Vertex Pharmaceuticals Incorporated company logo

# 1st Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations

Subscribe >> Deal exit on
Dec. 15, 2017
Deal entry on
Dec. 15, 2017
0.10%Expected margin
61.54% successful of 65 deals
$145.86 Last close price
at 15-dec-2017


Model's trade recommendations -2.10% Return for period

0.20% Annual return

$36.62B Market Cap

β 1.58  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period -2.10%
52wk return 18.65%
52wk Range
Sortino ratio 0.12
Sharpe ratio 0.09
Norm. RMSE 0.40%
Downside risk 14.93%
Volatility 19.85%
  • STRONG BUY Analysts consensus recommendation

Vertex Pharmaceuticals is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to their clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 248M
P/E 241.33
Shares Outstanding 253M
% Held by Insiders 1.80%
% Held by Institutions 93.33%
EPS (last reported FY) $-0.11
EPS (last reported Q) $0.24
EPS, estimated (last reported Q) $0.04
Total revenues $2 B
Net income $-0 B